
UB519
Targetsvoltage-gated sodium channel
IndicationsAnalgesia
ClinicalCN - II
TherapeuticsAnesthesiology
ModalitiesSmall Molecule
Exclusive Summary
- **Validated Non-Opioid Mechanism**: A potent Voltage-Gated Sodium Channel (VGSC) blocker with analgesic potency 2,900 times that of morphine, offering a non-addictive solution with no respiratory depression risk, addressing the global opioid crisis.
- **De-risked by Extensive Human Data**: The molecule is already NMPA-approved in China for detoxification (based on Phase III data with 520 subjects), providing a robust safety profile from over 800 human subjects to support global analgesia development.
- **High Entry Barrier Manufacturing**: Possesses proprietary technology for extracting high-purity Tetrodotoxin (TTX) from pufferfish viscera, overcoming global challenges in raw material sourcing and purification (European raw material price ~$400k/g).
Asset Materials

How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →